Clinical trial • Phase I • Immunology|Rare Disease
CTX112 for Systemic lupus erythematosus (SLE) | Systemic sclerosis | Idiopathic inflammatory myopathy (IIM)
Phase I trial of CTX112 for Systemic lupus erythematosus (SLE) | Systemic sclerosis | Idiopathic inflammatory myopathy (IIM). 63 participants.
Overview
- Trial Therapeutic Area
- Immunology|Rare Disease
- Trial Disease
- Systemic lupus erythematosus (SLE) | Systemic sclerosis | Idiopathic inflammatory myopathy (IIM)
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 20-12-2024
- First CTIS Authorization Date
- 14-04-2025
Trial design
Phase I trial across 8 sites in Germany, Spain.
- Target Sample Size
- 63
Recruitment
- Planned Sample Size
- 63
- Recruitment Window Months
- 61
Geography
- Total Number Of Sites
- 8
- Total Number Of Participants
- 38
Germany
- Earliest CTIS Part Ii Submission Date
- 21-02-2025
- Latest Decision Or Authorization Date
- 24-04-2026
- Processing Time Days
- 427
- Number Of Sites
- 5
- Number Of Participants
- 17
Sites
- Site Name
- Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
- Department Name
- -
- Contact Person Name
- Frank Behrens
- Contact Person Email
- frank.behrens@itmp.fraunhofer.de
- Site Name
- University Hospital Cologne AöR
- Department Name
- Innere Medizin I
- Contact Person Name
- Philipp Köhler
- Contact Person Email
- philipp.koehler@uk-koeln.de
- Site Name
- Medizinische Hochschule Hannover
- Department Name
- Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
- Contact Person Name
- Christian Schultze-Florey
- Contact Person Email
- Schultze-Florey.Christian@mh-hannover.de
- Site Name
- Universitaetsklinikum Augsburg
- Department Name
- II. Medizinische Klinik
- Contact Person Name
- Christoph Schmid
- Contact Person Email
- christoph.schmid@uk-augsburg.de
- Site Name
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
- Department Name
- III. Medizinische Klinik und Poliklinik
- Contact Person Name
- Eva Wagner-Drouet
- Contact Person Email
- Eva.Wagner@unimedizin-mainz.de
Spain
- Earliest CTIS Part Ii Submission Date
- 14-11-2025
- Latest Decision Or Authorization Date
- 24-04-2026
- Processing Time Days
- 161
- Number Of Sites
- 3
- Number Of Participants
- 21
Sites
- Site Name
- Hospital Universitario Reina Sofia
- Department Name
- Rheumatology
- Contact Person Name
- Maria Angeles Aguirre Zamorano
- Contact Person Email
- angeles.aguirre.sspa@juntadeandalucia.es
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Rheumatology
- Contact Person Name
- Enrique Ornilla Laraundogoitia
- Contact Person Email
- eornilla@unav.es
- Site Name
- University Hospital Virgen Del Rocio S.L.
- Department Name
- Rheumatology
- Contact Person Name
- Elena Alonso Blanco Morales
- Contact Person Email
- elenaabm@hotmail.com
Sponsor
Primary sponsor
- Full Name
- CRISPR Therapeutics AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Investigational products
- Investigational Product Name
- CTX112
Related trials
Other published trials that may interest you.
- DAZODALIBEP for Sjögren's syndrome
- rilzabrutinib for Immune thrombocytopenic purpura | Immune Thrombocytopenia Purpura
- DONIDALORSEN for Hereditary angioedema
- ALLOGENEIC ADIPOCYTE-DERIVED MESENCHYMAL STROMAL CELLS TRANSDUCED WITH A LENTIVIRAL PROVIRUS VECTOR CONTAINING THE HUMAN CXCR4 AND IL-10 GENES for Acute graft-versus-host disease (aGVHD) | Steroid-refractory acute graft-versus-host disease | Ruxolitinib-refractory acute graft-versus-host disease
- RILZABRUTINIB for Immune thrombocytopenia (ITP)|Autoimmune thrombocytopenia|Primary immune thrombocytopenia